We wanted to provide a couple of updates on Laminil.

First, Laminil has been granted US patent protection, an important milestone to investors.

Willowcroft Pharm continues to seek investors to finish the FDA regulatory approval process and get this drug to horses with laminitis.

On that front, Willowcroft Pharm has been selected to present at the 2015 Animal Health Investment Forum on Sept. 1 in Kansas City.

The forum offers one of the only opportunities for early stage companies in the animal health sector to present their vision and business plan to potential investors. Companies presenting at the forum have raised nearly $130 million. Several have also received licensing agreements or distribution contracts.

The forum showcases animal health and nutrition companies from throughout the world. It looks for companies that are seeking $500,000 to $20 million in funding with revenue projections of $20 million within five to seven years.

Kansas City is home to the KC Animal Health Corridor. Because of its significant animal health industry concentration, the corridor offers a uniquely supportive environment for early-stage entrepreneurs in the animal health and nutrition industry.

Presenting companies are judged by a panel of industry leaders. The strongest presenter of the day receives the Innovation Award.